Novo Nordisk Pharmatech has announced that it will be a part of the annual BioProcess International European Summit.

Held in Amsterdam from 23 April to 25 April, Novo Nordisk Pharmatech will be present at booth #8.

The compant invites you to visit its booth and discover more about recombinant insulin for innovative biologics and pharmaceutical grade quaternary ammonium compounds.

Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. Its recombinant insulin is a key component in serum-free growth media for mammalian cells and approved by regulatory bodies worldwide, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company’s products are also manufactured to current good manufacturing process (cGMP) standards.

Novo Nordisk Pharmatech guarantees:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

The firm delivers a proven record of product purity, reliability and consistency, and can even tailor high-quality products for future therapies

Chinese hamster ovary (CHO) cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media from serum-containing to serum-free and further on to chemically defined media.

In collaboration with Novo Nordisk Pharmatech, UAB has shown that the addition of animal origin-free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density.

In addition, insulin has been proven to aid in the expression of difficult to express proteins.

Please stop by Novo Nordisk Pharmatech’s booth for a talk on how insulin could play an important role in your upstream process for the chance to win an Amazon Kindle.